N/A N=60 Subcutaneous Fat Reduction in the Submental Area
Body Fat Disorder
Primary: Safety of CoolScupting in the Submental Area — 4 incidence of device- and/or procedure AE
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Non-invasive Cooling of Subcutaneous Fat
Fat Disorder
Primary: Change in Fat Layer Thickness of the Treated Flank — -18.7; -22.6; -17.8; -17.5 percent fat layer change
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Phase 4 N=16 Submental Study (Sequential Treatment Approach)
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
N/A N=40 Diagnostic Ultrasound for Measuring Fat of the Body
Subcutaneous Fat
Primary: Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body — .56; .60; .83; 1.65 average fat measurement (cm)
N/A N=14 Fat Reduction in the Submandibular/Submental Area
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos
N/A N=19 Fat Layer Reduction in the Lateral Thighs Using CoolSculpting
Body Fat Disorder
Primary: Safety of the Zeltiq CoolSculpting System in the Outer Thighs — 8; 0 events
N/A N=175 Non-Invasive Cooling of Fat Cells
Reduction of Unwanted Fat
Primary: Percentage of Participants With Visible Improvement in Treated Area — 65.2; 82.8 percentage of participants
N/A N=60 Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound
Treatment of Adipose Tissue in the Thighs
Primary: Clinical Improvement in Thigh Circumference — -1.22; -0.59 centimeter
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
N/A N=20 CoolSculpting in the Abdomen Using Applicator With and Without CCI
Body Fat Disorder
Primary: Percentage of Accurately Identified Pre-treatment Photos — 33; 23; 50; 23 photos
Phase 3 N=165 Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events (AEs) — 160; 7; 11; 15 participants
Phase 3 N=793 Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Central Abdominal Bulging
Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397
N/A N=60 Non-Invasive Reduction of Abdominal Fat
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
N/A N=19 Bilateral; Flank Study With Crown Cooling Insert
Body Fat Disorder
Primary: Percentage of Correctly Identified Pre-treatment Photos by a Panel of Blinded Independent Reviewers — 16; 15 photos
N/A N=39 Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
N/A N=45 Non-Invasive Reduction of Fat in the Inner Thighs
Body Fat Disorder
Primary: Percentage of Pre-Treatment Images Correctly Identified by Reviewers — 90.5 percentage of correct identifications
N/A N=45 CoolSculpting of the Flank With Alternate Treatment Parameters
Body Fat Disorder
Primary: The Number of Device and/or Procedure-Related Adverse Events — 12 device or procedure-related AEs
Phase 3 N=516 Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Moderate or Severe Submental Fullness
Primary: Percentage of Participants Who Achieved a Composite 1-grade Response — 66.5; 22.2 percentage of participants — p=<0.001
Phase 3 N=506 Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Moderate or Severe Submental Fullness
Primary: Percentage of Participants Who Achieved a Composite 1-grade Response — 70.0; 18.6 percentage of participants — p=<0.001
N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
Phase 2 N=129 Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study
Moderate or Severe Submental Fullness
Primary: Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores — -0.7; -0.8; -0.4 units on a scale — p=0.052
N/A N=10 Measurement of Body Fat in Infants
Brown Adipose Tissue · Body Composition
Primary: Whole Body Fat Mass — 20.8 percentage of fat mass
N/A N=12 Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat
Body Fat
Primary: Number of Participants Who's Abdominal Tissue Showed Necrosis or Inflammatory Immune Cell Response — 10; 0 Participants
Phase 2 N=25 A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Subcutaneous Fat
Primary: Number of Treatment Emergent Adverse Events — 103; 57; 69; 61 number of events
Phase 3 N=363 Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 59.2; 65.3; 23.0 percentage of participants — p=<0.001
Phase 3 N=360 Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 58.3; 62.3; 34.5 percentage of participants — p=<0.001
Early Phase 1 N=15 Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat
Adiposity
Primary: Number of Participants With Adverse Events — 08; 01; 02 participants
Phase 2 N=73 Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events — 24; 13; 20; 14 participants